{"entity":{"id":"nct04680052","kind":"trial","name":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa","aka":["InMIND","inMIND","Tafasitamab with lenalidomide and rituximab in relapsed or refractory follicular lymphoma"],"tldr":"A phase 3 trial of Tafasitamab, Rituximab, Lenalidomide in follicular lymphoma, run by Incyte Corporation, active and no longer recruiting.","summary":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. is a phase 3 interventional study registered as NCT04680052 by Incyte Corporation, with 654 participants enrolled, started 2021-04-15 and due to reach its primary completion in 2024-02-23. Interventions recorded: tafasitamab, rituximab, lenalidomide, placebo. Conditions listed: Follicular Lymphoma, Marginal Zone Lymphoma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04680052","url":"https://clinicaltrials.gov/study/NCT04680052"}],"tags":["ctgov-ingest"],"related":["lymphoma-roadmap","paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026","rosewood"],"cancers":["follicular-lymphoma","marginal-zone-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":["monoclonal-antibody","protac-degrader"],"targets":["cd19","cd20"],"drugs":["tafasitamab","rituximab","lenalidomide"],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04680052","phase":"3","setting":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma","sponsor":"Incyte Corporation","result":"Median investigator-assessed progression-free survival 22.4 against 13.9 months (hazard ratio 0.43, 95 per cent confidence interval 0.32 to 0.58).","started":"2021-04-15","startedType":"actual","yearReported":2025,"enrolled":654,"enrolledBasis":"registry","outcomes":[{"endpoint":"FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First","primary":true,"unit":"months","arms":[{"name":"FL: Tafasitamab + Rituximab + Lenalidomide","n":273,"value":22.37,"note":"95% CI 19.22 to NA; Figures from the ClinicalTrials.gov results section (first posted 2025-04-04), not from a publication"},{"name":"FL: Placebo + Rituximab + Lenalidomide","n":275,"value":13.93,"note":"95% CI 11.53 to 16.39"}],"source":"https://clinicaltrials.gov/study/NCT04680052?tab=results"}]},"route":"/trials/nct04680052/","neighbours":{"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}],"paper":[{"id":"paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026","kind":"paper","name":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial","route":"/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/"}],"trial":[{"id":"rosewood","kind":"trial","name":"ROSEWOOD","route":"/trials/rosewood/"}],"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"drug":[{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}]}}